SCHEMBL29466139

CC(=O)N[C@@H]1[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O[C@@H]4O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]4O)[C@H](O[C@@H]4O[C@H](CO)[C@H](O)[C@H](O[C@]5(C(=O)O)C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O5)[C@H]4O)[C@H]3NC(C)=O)[C@H]2O)[C@@H](CO)O[C@H]1O

nearest known ligand 0.80

Predicted protein targets (top 5)

	gene	UniProt	supporting neighbours	confidence
▸	SELP	P16109	2/20	0.70

▸	SELL	P14151	1/20	0.70

▸	SELE	P16581	5/20	0.64

▸	MAG	P20916	6/20	0.61

▸	SIGLEC7	Q9Y286	6/20	0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL29466129	1.00	SELP (0.70)	SELPSELLSELEMAGSIGLEC7
SCHEMBL29407985	0.99	SELP (0.71)	SELPSELLSELEMAGSIGLEC7
SCHEMBL31010809	0.98	SELP (0.71)	SELPSELLSELEMAGSIGLEC7
SCHEMBL13195877	0.98	SELP (0.73)	SELPSELLSELEMAGSIGLEC7
SCHEMBL29448496	0.98	SELP (0.73)	SELPSELLSELEMAGSIGLEC7
SCHEMBL29405702	0.98	SELP (0.73)	SELPSELLSELEMAGSIGLEC7
SCHEMBL29391699	0.98	SELP (0.73)	SELPSELLSELEMAGSIGLEC7
SCHEMBL29389517	0.98	SELP (0.73)	SELPSELLSELEMAGSIGLEC7
SCHEMBL29372449	0.98	SELP (0.73)	SELPSELLSELEMAGSIGLEC7
SCHEMBL13978771	0.98	SELP (0.73)	SELPSELLSELEMAGSIGLEC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-12552876-B2	Anti-fucosyl-GM1 antibodies	SCANCELL LIMITED (GB)	2026-02-17	—	—	US	disclosed
EP-4025612-B1	ANTI-FUCOSYL-GM1 ANTIBODIES	SCANCELL LTD (GB)	2025-10-29	—	—	EP	disclosed
US-20220267466-A1	ANTI-FUCOSYL-GM1 ANTIBODIES	SCANCELL LIMITED (GB)	2022-08-25	—	—	US	disclosed
CN-108137695-B	Sialylated diluisia a expressed on glycoproteins other than glycolipids as a functional cancer target and antibodies thereto	斯坎塞尔有限公司	2022-03-29	—	—	CN	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-12552876-B2	Anti-fucosyl-GM1 antibodies	FUCA1, FUCA2, SIGLEC7	SELP 1683/4885SELL 536/4885SELE 1033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.